Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huahai Pharmaceutical
- Announcement on the Subsidiary Passing On-site Inspection by FDA
- Announcement on Not Revising Downward the Conversion Price of ""HUAHAI Convertible Bonds"
- Report for Q3 2025
- Announcement on Products Being Prospective Winners in the 11th National Centralized Drug Procurement
Later from Zhejiang Huahai Pharmaceutical
- Announcement on Progress in Drug Clinical Trials by Subsidiary
- Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial
- Announcement on Optional Repurchase Results of "Huahai Convertible Bonds"
- Announcement on Release of Pledge of Partial Equity of Shareholder
- On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025
Follow Zhejiang Huahai Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huahai Pharmaceutical